Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study

Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study

ObjectiveWe evaluated the efficacy and safety of transarterial chemoembolization (TACE) combined with apatinib plus PD-1 inhibitors (TACE-AP) compared with TACE combined with apatinib (TACE-A) in patients with advanced hepatocellular carcinoma (HCC) and to explore the prognostic factors affecting pa...

Full description

Bibliographic Details
Main Authors: Wei-Li Xia, Xiao-Hui Zhao, Yuan- Guo, Guang-Shao Cao, Gang Wu, Wei-Jun Fan, Quan-Jun Yao, Shi-Jun Xu, Chen-Yang Guo, Hong-Tao Hu, Hai-Liang Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
transarterial chemoembolization
apatinib
PD-1 inhibitors
propensity score matching
random survival forest (RSF)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.961394/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.961394/full

Similar Items